Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) Stock Price

MRVIStock

$6.79+94.56%52W

Market Cap$2.51B

P/E—

PEG Ratio—

Div yield—

Beta0.63

MRVI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)97.11%

Price vs S&P 500 (4W)-3.97%

VGM Score48.21

P/CF (Annual)121.94x

Book Value / Share (Quarterly)$0.79

P/TBV (Annual)13.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-40.53%

Cash Flow / Share (Quarterly)$-0.14

Price vs S&P 500 (YTD)97.00%

Gross Margin (TTM)34.89%

Net Profit Margin (TTM)-37.07%

EPS (TTM)$-0.53

10-Day Avg Trading Volume2.93M

EPS Excl Extra (TTM)$-0.53

Revenue Growth (5Y)-8.15%

EPS (Annual)$-0.91

ROI (Annual)-24.43%

Gross Margin (Annual)18.30%

Net Profit Margin (5Y Avg)-23.96%

Cash / Share (Quarterly)$0.27

Revenue Growth QoQ (YoY)8.53%

ROA (Last FY)-16.97%

Revenue Growth TTM (YoY)-3.28%

EBITD / Share (TTM)$-0.74

ROE (5Y Avg)-7.32%

Operating Margin (TTM)-57.52%

Cash Flow / Share (Annual)$-0.28

P/B Ratio8.62x

P/B Ratio (Quarterly)7.87x

Net Income / Employee (Annual)$-300,600

EV / Revenue (TTM)8.96x

Net Interest Coverage (TTM)-14.11x

ROA (TTM)-10.54%

EV / EBITDA (TTM)21.39x

EPS Incl Extra (Annual)$-0.91

Current Ratio (Annual)6.60x

Quick Ratio (Quarterly)2.63x

3-Month Avg Trading Volume3.24M

52-Week Price Return94.56%

EV / Free Cash Flow (Annual)3.16x

Revenue / Employee (TTM)$479,900

Tangible BV / Share (Quarterly)$0.26

P/S Ratio (Annual)9.49x

Asset Turnover (Annual)0.24x

52-Week High$9.42

Operating Margin (5Y Avg)-16.92%

EPS Excl Extra (Annual)$-0.91

CapEx CAGR (5Y)-12.34%

26-Week Price Return107.01%

Quick Ratio (Annual)5.40x

13-Week Price Return-6.22%

Total Debt / Equity (Annual)1.52x

Current Ratio (Quarterly)4.05x

Enterprise Value$1.87B

Revenue / Share Growth (5Y)3.13%

Asset Turnover (TTM)0.28x

Book Value / Share Growth (5Y)19.28%

Revenue / Employee (Annual)$427,000

Inventory Turnover (Annual)3.35x

Pretax Margin (Annual)-126.50%

Cash / Share (Annual)$0.85

3-Month Return Std Dev81.88%

Gross Margin (5Y Avg)54.38%

Net Income / Employee (TTM)$-177,900

EBITDA Interim CAGR (5Y)-50.59%

ROE (Last FY)-61.58%

Net Interest Coverage (Annual)-7.67x

EPS Basic Excl Extra (Annual)$-0.91

P/FCF (TTM)224.61x

Receivables Turnover (TTM)7.07x

EV / Free Cash Flow (TTM)38.73x

Total Debt / Equity (Quarterly)0.86x

EPS Incl Extra (TTM)$-0.53

Receivables Turnover (Annual)5.80x

ROI (TTM)-15.72%

P/S Ratio (TTM)8.45x

Pretax Margin (5Y Avg)23.06%

Revenue / Share (Annual)$1.29

Tangible BV / Share (Annual)$0.24

Price vs S&P 500 (52W)79.02%

Year-to-Date Return108.92%

5-Day Price Return-3.82%

EPS Normalized (Annual)$-0.91

ROA (5Y Avg)-4.04%

Net Profit Margin (Annual)-70.41%

Month-to-Date Return-11.36%

Cash Flow / Share (TTM)$0.75

EBITD / Share (Annual)$-1.47

Operating Margin (Annual)-115.89%

LT Debt / Equity (Annual)1.35x

ROI (5Y Avg)-3.36%

LT Debt / Equity (Quarterly)0.71x

EPS Basic Excl Extra (TTM)$-0.53

P/TBV (Quarterly)24.32x

P/B Ratio (Annual)3.91x

Inventory Turnover (TTM)3.09x

Pretax Margin (TTM)-65.38%

Book Value / Share (Annual)$0.83

Price vs S&P 500 (13W)-8.90%

Beta0.63x

P/FCF (Annual)29.06x

Revenue / Share (TTM)$1.41

ROE (TTM)-35.42%

52-Week Low$2.54

vGradeD

gGradeD

mGradeB

vgmGradeC

MRVI Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.04	-$0.02	+54.51%(+$0.02)
Q1 2026	May 7, 2026	-$0.05	$0.01	+121.02%(+$0.06)
Q4 2025	Feb 25, 2026	-$0.07	-$0.04	+43.00%(+$0.03)
Q3 2025	Nov 6, 2025	-$0.08	-$0.08	+2.75%(+$0.00)
Q2 2025	Aug 11, 2025	-$0.07	-$0.08	-8.23%(-$0.01)

MRVI Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.88

3.93

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
MRVIMaravai LifeSciences Holdings, Inc. Class A Common Stock	D	D	B	8.4x	-3.3%	34.9%	—	$6.79
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Maravai LifeSciences Holdings, Inc. Class A Common Stock

Maravai LifeSciences provides critical enabling technologies and services for pharmaceutical and biotechnology companies developing drugs, vaccines, and diagnostics. The company operates through two segments: TriLink, which supplies nucleic acid products including mRNA and oligonucleotides; and Cygnus, which provides biologics safety testing and quality assurance solutions. Its products serve customers throughout drug development, manufacturing, and quality assurance processes.

MRVI Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.06

Revenue estimate$43.56M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

DNLIDenali Therapeutics Inc. Common StockBiological Products
FULH.B. Fuller CompanyAdhesives & Sealants
WDFCWd-40 CoIndustrial Chemicals
NEOGNeogen CorpIn Vitro Diagnostics
BEAMBeam Therapeutics Inc. Common StockBiological Products
NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products
IOSPInnospec Inc.Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$2.54

High$9.42